Posted by Michael Wonder on 03 May 2019
ICER publishes evidence report on the use of siponimod to treat secondary progressive multiple sclerosis
2 May 2019 - Midwest CEPAC to deliberate on the treatment’s clinical effectiveness and other potential benefits during its May 23 public meeting.
The Institute for Clinical and Economic Review (ICER) today released an evidence report assessing the comparative clinical effectiveness and value of siponimod (Mayzent, Novartis) for the treatment of secondary progressive multiple sclerosis (SPMS).
Siponimod was recently approved by the FDA for the treatment of relapsing forms of multiple sclerosis, including active SPMS. However, ICER’s assessment focuses on the clinical and cost-effectiveness of siponimod for all patients with SPMS (both active and non-active), which was the population studied in the phase III trial.
